GENETIC TECHNOLOGY NEWS

摘要

deCODE Starts Heart Drug Phase III Clinical Trial; Peregrine Monoclonal Inhibits Bird Flu Virus; GTN Strategic Partners; Some Important Patents for You To Check; GTN Market Forecast: SMA Therapeutics; 2nd Annual New Product Development & Marketing andEmerging Technologies Executive Mindxchanges; ALNYLAM siRNAANTIVIRALS AGAINST FLU: Alnylam Pharmaceuticals Inc. has reported favorable phase I clinical results for ALN-RSVO1, its small interfering RNA (siRNA) drug candidate designed for prevention and treatment of respiratory syncytial virus infection (GTN 12/16/05). Now Alnylam and its collaborators have presented preclinical data on other siRNAs for treating pandemic influenza and other respiratory diseases at the recent American Thoracic Society (ATS) International Congress in San Diego, CA. The other respiratory diseases included asthma, chronic obstructive pulmonary disorder (COPD), and idiopathic pulmonary fibrosis (IFF).